Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00783172 · ClinicalTrials.gov registry record · Phase 1
Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer
A Phase 1 study, sponsored by Milton S. Hershey Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT00783172: Clinical Trial Phase 1 study, sponsored by Milton S. Hershey Medical Center.
NCT00783172 is a Phase 1 study that was terminated before completion, run by Milton S. Hershey Medical Center. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00783172, a Phase 1 study, was terminated before completion, sponsored by Milton S. Hershey Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
It is hypothesized that OGF biotherapy may be safely administered in combination with gemcitabine to individuals with unresectable pancreatic cancer. The study includes two aims, the first is to evaluate the safety and toxicity of the combination of OGF and gemcitabine chemotherapy. The second aim of the trial is to study the efficacy of OGF and gemcitabine when used in combination.
Interventions
- DRUG Gemcitabine
- BIOLOGICAL Opioid Growth Factor (OGF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Why NCT00783172 stopped before completion
NCT00783172 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00783172 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00783172 about?
NCT00783172 is a clinical study titled "Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer". It is hypothesized that OGF biotherapy may be safely administered in combination with gemcitabine to individuals with unresectable pancreatic cancer. The study includes two aims, the first is to evaluate the safety and toxicity of the combination of OGF and gemcitabine chemotherapy. The second aim o...
What is the current status of trial NCT00783172?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2009-01. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00783172?
The interventions under investigation include: Gemcitabine (DRUG), Opioid Growth Factor (OGF) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00783172?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00783172's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia